JP2021500373A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500373A5
JP2021500373A5 JP2020523010A JP2020523010A JP2021500373A5 JP 2021500373 A5 JP2021500373 A5 JP 2021500373A5 JP 2020523010 A JP2020523010 A JP 2020523010A JP 2020523010 A JP2020523010 A JP 2020523010A JP 2021500373 A5 JP2021500373 A5 JP 2021500373A5
Authority
JP
Japan
Prior art keywords
group
alkyl
compound according
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020523010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/057086 external-priority patent/WO2019083990A2/en
Publication of JP2021500373A publication Critical patent/JP2021500373A/ja
Publication of JP2021500373A5 publication Critical patent/JP2021500373A5/ja
Priority to JP2024078640A priority Critical patent/JP2024109682A/ja
Pending legal-status Critical Current

Links

JP2020523010A 2017-10-23 2018-10-23 線維芽細胞活性化タンパク質α(FAP−α)を標的とする撮像剤および放射線療法用薬剤 Pending JP2021500373A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078640A JP2024109682A (ja) 2017-10-23 2024-05-14 線維芽細胞活性化タンパク質α(FAP-α)を標的とする撮像剤および放射線療法用薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575607P 2017-10-23 2017-10-23
US62/575,607 2017-10-23
PCT/US2018/057086 WO2019083990A2 (en) 2017-10-23 2018-10-23 IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078640A Division JP2024109682A (ja) 2017-10-23 2024-05-14 線維芽細胞活性化タンパク質α(FAP-α)を標的とする撮像剤および放射線療法用薬剤

Publications (2)

Publication Number Publication Date
JP2021500373A JP2021500373A (ja) 2021-01-07
JP2021500373A5 true JP2021500373A5 (enExample) 2021-12-02

Family

ID=66247306

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523010A Pending JP2021500373A (ja) 2017-10-23 2018-10-23 線維芽細胞活性化タンパク質α(FAP−α)を標的とする撮像剤および放射線療法用薬剤
JP2024078640A Pending JP2024109682A (ja) 2017-10-23 2024-05-14 線維芽細胞活性化タンパク質α(FAP-α)を標的とする撮像剤および放射線療法用薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078640A Pending JP2024109682A (ja) 2017-10-23 2024-05-14 線維芽細胞活性化タンパク質α(FAP-α)を標的とする撮像剤および放射線療法用薬剤

Country Status (12)

Country Link
US (5) US20200330624A1 (enExample)
EP (1) EP3700580A4 (enExample)
JP (2) JP2021500373A (enExample)
KR (2) KR102764076B1 (enExample)
CN (2) CN111511408A (enExample)
AU (2) AU2018355222B2 (enExample)
BR (1) BR112020008011A2 (enExample)
CA (1) CA3088138A1 (enExample)
EA (1) EA202090776A1 (enExample)
IL (1) IL274088A (enExample)
MX (2) MX2020004807A (enExample)
WO (1) WO2019083990A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
MX2020006128A (es) * 2017-12-15 2020-09-21 Praxis Biotech LLC Inhibidores de la proteina de activacion de fibroblastos.
AU2019219057B2 (en) * 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor
CA3116313A1 (en) 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
EP3898654A4 (en) 2018-12-21 2022-10-26 Praxis Biotech LLC FIBROBLAST ACTIVATION PROTEIN INHIBITORS
SI3997103T1 (sl) 2019-07-08 2025-04-30 3B Pharmaceuticals Gmbh Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN118930608A (zh) 2019-07-08 2024-11-12 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
MX2022003215A (es) * 2019-09-17 2022-04-25 Purdue Research Foundation Formacion de imagenes especificas para proteina de activacion de fibroblastos (fap) y terapia contra tipos de cancer y otras enfermedades fibroticas e inflamatorias.
EP4096676A4 (en) * 2020-01-31 2024-04-10 Purdue Research Foundation FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY
EP3891138B1 (en) 2020-02-12 2022-01-12 Philochem AG Fibroblast activation protein ligands for targeted delivery applications
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
WO2021234181A1 (en) * 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
CN112138175A (zh) * 2020-09-01 2020-12-29 上海市质子重离子临床技术研发中心 一种放射性核素99mTc标记FAPI的化合物的制备方法
CN114790194B (zh) * 2020-12-21 2024-03-26 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3206863A1 (en) * 2021-01-07 2022-07-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CA3210863C (en) * 2021-02-10 2024-06-04 Yantai Lannacheng Biotechnology Co., Ltd. Truncated evans blue modified fibroblast activation protein inhibitor, preparation method and application thereof
MX2023009486A (es) 2021-02-12 2023-10-16 Philochem Ag Ligandos bivalentes de la proteína de activación de fibroblastos para aplicaciones de entrega dirigida.
EP4043452A1 (en) 2021-02-12 2022-08-17 Philochem AG Bivalent fibroblast activation protein ligands for targeted delivery applications
CN113105432B (zh) * 2021-03-30 2022-03-04 上海交通大学医学院附属仁济医院 一种碳-11(11c)放射性药物及其制备方法和应用
CA3214070A1 (en) * 2021-04-02 2022-10-06 Sangeeta Banerjee RAY Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen
CN113277989B (zh) * 2021-04-27 2022-05-31 中南大学湘雅医院 一种68Ga标记的分子探针、制备方法及其应用
AU2022275579C1 (en) * 2021-05-19 2024-08-22 Ferronova Pty Ltd Mapping nanoparticles
CN113527266A (zh) * 2021-06-23 2021-10-22 上海健康医学院 一种靶向fap的双氧水响应的前药及其制备方法与应用
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4122499A1 (en) * 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof
TW202320805A (zh) * 2021-08-18 2023-06-01 美商杜夫特學院信託管理公司 用於pet造影之選擇性靶向纖維母細胞活化蛋白之放射性氟標誌試劑
CN113880810B (zh) * 2021-09-24 2023-02-28 厦门大学 一种核素标记的配合物及其制备方法和应用
CA3234394A1 (en) 2021-10-04 2023-04-13 Philochem Ag Radiolabelled fibroblast activation protein ligands
TW202317541A (zh) 2021-10-28 2023-05-01 行政院原子能委員會核能研究所 一種靶向成纖維細胞活化蛋白之化合物或其鹽,其製備方法及其用途
WO2023081301A1 (en) * 2021-11-05 2023-05-11 On Target Laboratories, LLC Fibroblast activation protein targeted dyes their related uses
US20250177582A1 (en) 2022-01-30 2025-06-05 Philochem Ag High-affinity ligands of fibroblast activation protein for targeted delivery applications
AU2023223808A1 (en) 2022-02-22 2024-09-19 Osaka University RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF
JP2025513317A (ja) * 2022-04-21 2025-04-24 シャンハイ シノタウ バイオテック. シーオー., エルティーディー Fap阻害剤
WO2023222558A1 (en) 2022-05-14 2023-11-23 Zounek Alexis Nikolai Precursor and theranostic radiotracer with improved tumor retention
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
CA3262480A1 (en) * 2022-07-28 2024-02-01 Ratio Therapeutics, Inc. Compositions targeting fibroblast-activating proteins and their methods of use
CN115368342B (zh) * 2022-08-24 2024-01-23 西南医科大学附属医院 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用
JP2025529319A (ja) 2022-09-06 2025-09-04 フィロケム・アーゲー 標的送達用途のための多価線維芽細胞活性化タンパク質リガンド
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
EP4590345A2 (en) * 2022-09-23 2025-07-30 Nuclidium AG High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
WO2024078592A1 (zh) * 2022-10-14 2024-04-18 无锡诺宇医药科技有限公司 靶向成纤维细胞活化蛋白的药物及其应用
WO2024165072A1 (zh) * 2023-02-10 2024-08-15 成都纽瑞特医疗科技股份有限公司 一种多肽化合物及其应用
CN120957982A (zh) 2023-05-08 2025-11-14 江苏恒瑞医药股份有限公司 靶向成纤维细胞活化蛋白的配体
WO2025029608A1 (en) * 2023-07-28 2025-02-06 Ratio Therapeutics, Inc. Fibroblast activation protein-targeted compositions and methods of use thereof
WO2025046043A1 (en) 2023-08-31 2025-03-06 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer
WO2025063849A2 (en) 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025125335A1 (en) 2023-12-13 2025-06-19 Radiovaxx Gmbh Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group
WO2025125621A1 (en) 2023-12-14 2025-06-19 Radiovaxx Gmbh Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers
WO2025146433A1 (en) 2024-01-05 2025-07-10 Radiovaxx Gmbh Precursor and theranostic radiotracer with prolonged tumor retention
CN118063689B (zh) * 2024-01-26 2025-01-28 锐康九域(厦门)医药科技有限公司 成纤维细胞激活蛋白-α响应水解致电荷翻转的聚合物-药物偶联物及其制备方法和应用
CN118271393B (zh) * 2024-05-31 2024-09-03 中国药科大学 一种靶向fap的二聚化合物及其探针和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399869B2 (en) * 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
HUE034027T2 (en) 2008-08-01 2018-01-29 Univ Johns Hopkins Psma-binding agents and uses thereof
EP2349995A1 (en) * 2008-09-25 2011-08-03 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
CA2755965C (en) 2009-03-19 2019-04-16 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2016149188A1 (en) * 2015-03-13 2016-09-22 The Johns Hopkins University 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
US20150320892A1 (en) * 2012-06-29 2015-11-12 Ge Healthcare Limited Imaging fibrosis
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
GB2538023A (en) * 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
US10736974B2 (en) * 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US10857246B2 (en) * 2015-06-01 2020-12-08 The Johns Hopkins University Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
AU2019219057B2 (en) 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor

Similar Documents

Publication Publication Date Title
JP2021500373A5 (enExample)
Butte et al. Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors
RU2350355C9 (ru) Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии
DE60133626T2 (de) Hydrophile zyaninfarbstoffe
JP5416970B2 (ja) ニコチン酸及びピコリン酸誘導近赤外線蛍光団
EP2764406B1 (en) Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
Owens et al. Near-infrared illumination of native tissues for image-guided surgery
Cai et al. Near‐infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases
AU2016208387A1 (en) Charge-balanced imaging agents
JP2002526458A5 (enExample)
JP2000095758A (ja) 近赤外蛍光造影剤および蛍光造影方法
DE60106389T2 (de) Vielseitige hydrophile farbstoffe
BRPI0512893B1 (pt) métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrômico para doença associada com a deposição amilóide e respectivos compostos
JP2019512500A (ja) Ca ix標的nir色素及びそれらの使用
Zhou et al. Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield
JP5106397B2 (ja) 生体適合性n,n−二置換スルホンアミド含有蛍光色素標識
EP1937676A1 (en) Biocompatible fluorescent imaging agents
Xu et al. Design, synthesis, and in vitro and in vivo evaluation of high affinity and specificity near-infrared fluorescent bombesin antagonists for tumor imaging
Yang et al. Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging
CN111989324A (zh) 靶向化合物及其生产方法
CN106008374B (zh) 吡嗪类化合物及其在医药上的用途
EP4626487A2 (en) Crgd -conjugated imaging agent
JP2003510294A (ja) 手術中に腫瘍の周縁を視覚化するための、血管新生の標的構造物に対する抗体−色素結合物
US20220387632A1 (en) Renal clearable fluorescent contrast agent with increased tumor specificity, and imaging method using same
US7326403B2 (en) Radioactive iodine-labeled compound